The Office of Fair Trading report: a prescription for value-based drug pricing.
作者信息
Minhas Rubin, Moon James C
机构信息
Medway PCT, 7-8 Ambley Green, Bailey Drive, Gillingham, Kent ME8 0NJ, UK.
出版信息
J R Soc Med. 2007 May;100(5):216-8. doi: 10.1177/014107680710000510.
Abstract
摘要
相似文献
1
The Office of Fair Trading report: a prescription for value-based drug pricing.公平交易办公室报告：基于价值的药品定价方案
J R Soc Med. 2007 May;100(5):216-8. doi: 10.1177/014107680710000510.
2
Value based pricing for NHS drugs: an opportunity not to be missed?英国国家医疗服务体系（NHS）药品的基于价值的定价：一个不容错过的机遇？
BMJ. 2008 Feb 2;336(7638):251-4. doi: 10.1136/bmj.39434.500185.25.
3
Government pushes ahead with plan for cheaper drugs deal for NHS.政府推进为国民医疗服务体系达成更便宜药品交易的计划。
BMJ. 2007 Aug 11;335(7614):273. doi: 10.1136/bmj.39300.405822.DB.
4
Should NICE's threshold range for cost per QALY be raised? No.国家卫生与临床优化研究所（NICE）每质量调整生命年（QALY）的成本阈值范围应该提高吗？不应该。
BMJ. 2009 Jan 26;338:b185. doi: 10.1136/bmj.b185.
5
Should NICE's threshold range for cost per QALY be raised? Yes.国家卫生与临床优化研究所（NICE）每质量调整生命年（QALY）的成本阈值范围应该提高吗？应该。
BMJ. 2009 Jan 26;338:b181. doi: 10.1136/bmj.b181.
6
Straight talk with... Mark Sculpher. Interview by Kate Ravilious.坦诚对话……马克·斯库勒普访谈。采访者：凯特·雷维利乌斯。
Nat Med. 2012 Sep;18(9):1315. doi: 10.1038/nm0912-1315.
7
How NICE may be outflanked.英国国家卫生与临床优化研究所（NICE）可能如何被智取。
BMJ. 2006 May 27;332(7552):1268-71. doi: 10.1136/bmj.332.7552.1268.
8
OFT, VBP: QED?开放获取出版、价值为本定价：证明完毕？
Health Econ. 2007 Jun;16(6):545-58. doi: 10.1002/hec.1249.
9
'Irrational' prescription system must be changed.
Br J Nurs. 2002;11(1):11.
10
Value-based pricing of drugs in the UK.英国药品的基于价值的定价
Lancet. 2007 Apr 28;369(9571):1415-1416. doi: 10.1016/S0140-6736(07)60648-5.
引用本文的文献
1
Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.价格-数量法在价值定价不足的创新药物案例中的应用：意大利实际经验描述
Clin Drug Investig. 2016 Aug;36(8):599-603. doi: 10.1007/s40261-016-0408-9.
2
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal.澳大利亚生物/纳米制药政策面临的挑战：可持续产业复兴中的贸易协定、公共产品与参考定价
Aust New Zealand Health Policy. 2007 Jun 1;4:9. doi: 10.1186/1743-8462-4-9.
本文引用的文献
1
Statins audit: wrong question, wrong conclusions.
Lancet. 2007 Feb 24;369(9562):640. doi: 10.1016/S0140-6736(07)60306-7.
2
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.在基层医疗环境中，评估将患者从阿托伐他汀换用辛伐他汀以及从氯沙坦换用坎地沙坦的成本节约和临床结果。
Int J Clin Pract. 2007 Jan;61(1):15-23. doi: 10.1111/j.1742-1241.2006.01217.x.
3
Statin utilisation--recognising the role of the invisible hand.
Int J Clin Pract. 2007 Jan;61(1):3-6. doi: 10.1111/j.1742-1241.2006.01248.x.
4
How to lose a billion pounds.如何减掉十亿磅。
Int J Clin Pract. 2007 Jan;61(1):2-3. doi: 10.1111/j.1742-1241.2006.01221.x.
5
Switching statins.更换他汀类药物。
BMJ. 2006 Jun 10;332(7554):1344-5. doi: 10.1136/bmj.332.7554.1344.
6
NICE to rule on influenza flu drug zanamivir.英国国家卫生与临床优化研究所将对流感药物扎那米韦做出裁决。
BMJ. 1999 Oct 9;319(7215):937. doi: 10.1136/bmj.319.7215.937.
7
Regulating the price of the UK's drugs: second thoughts after the government's first report.英国药品价格监管：政府首份报告后的再思考
BMJ. 1997 Feb 1;314(7077):365-8. doi: 10.1136/bmj.314.7077.365.
Zotero 插件